tiprankstipranks
Trending News
More News >
Bwx Technologies Inc (BWXT)
NYSE:BWXT

BWX Technologies (BWXT) AI Stock Analysis

Compare
1,507 Followers

Top Page

BWXT

BWX Technologies

(NYSE:BWXT)

Select Model
Select Model
Select Model
Neutral 64 (OpenAI - 5.2)
Rating:64Neutral
Price Target:
$212.00
â–²(2.69% Upside)
Action:ReiteratedDate:02/24/26
The score is anchored by solid underlying financial performance and a strong, guidance-backed earnings-call outlook with meaningful backlog-driven visibility. Offsetting these positives are elevated valuation (high P/E with a low yield) and only mixed near-term technicals, plus balance-sheet re-levering risk highlighted in the financial statements.
Positive Factors
Backlog-driven revenue visibility
A $7.3B backlog (50% YoY growth) provides multi-year revenue visibility that underpins predictable cash flow and reduces near-term demand risk. Durable government and commercial contracts smooth revenue timing, supporting steady capacity utilization and strategic investment planning.
Commercial segment momentum & acquisitions
Rapid commercial growth, aided by acquisitions (AOT, Kinectrics) and a strong book-to-bill, diversifies revenue away from government work. This builds scale in higher-growth commercial nuclear, enhances technical/licensing capabilities, and supports sustainable margin improvement over coming years.
Improved liquidity and financing actions
Executing a $1.25B convertible and ending with $1.7B liquidity strengthens financial flexibility to fund capex, M&A and program ramps. Refinancing reduced near-term cost pressure, lowering refinancing risk and enabling strategic investments during multi-year contract executions.
Negative Factors
Rising leverage
Material re-levering to ~1.64 D/E reduces financial flexibility and raises interest-rate sensitivity. Higher leverage constrains capital allocation, raises refinancing risk if rates stay elevated, and limits ability to absorb execution slips on long-duration government programs.
Regulatory/product uncertainty (Tech 99)
Unresolved Tech 99 filtration and concentration issues create upside uncertainty: revenues are excluded from guidance until fixed. Delay or failed approval would postpone expected medical growth and weaken anticipated commercial margins tied to isotope product scaling.
Low front-end margins from new defense programs
Early-stage defense fuels and HPDU contracts demand heavy upfront investment and deliver lower initial margins, pressuring near-term segment profitability. A back-half weighting in results and margin dilution risk persist until capacity and pricing normalize, stressing short-term margin stability.

BWX Technologies (BWXT) vs. SPDR S&P 500 ETF (SPY)

BWX Technologies Business Overview & Revenue Model

Company DescriptionBWX Technologies, Inc. manufactures and sells nuclear components in the United States, Canada, and internationally. It operates in three segments: Nuclear Operations Group, Nuclear Power Group, and Nuclear Services Group. The Nuclear Operations Group segment provides precision naval and critical nuclear components, reactors, nuclear fuel, and assemblies for the United States Department of Energy/National Nuclear Security Administration's Naval Nuclear Propulsion Program and other uses; missile launch tubes for United States Navy submarines; close-tolerance and equipment for nuclear applications; and converts Cold War-era government stockpiles of high-enriched uranium, as well as receives, stores, characterizes, dissolves, recovers, and purifies uranium-bearing materials; supplies research reactor fuel elements for colleges, universities, and national laboratories; and components for defense applications. The Nuclear Power Group segment offers commercial nuclear steam generators, nuclear fuel, fuel handling systems, pressure vessels, reactor components, heat exchangers, tooling delivery systems, and containers; engineering and in-plant services for nuclear power plants; designs, manufactures, commissions, and services nuclear power generation equipment; in-plant inspection, maintenance, and modification services, as well as non-destructive examination and tooling/repair solutions; and supplies medical radioisotopes and radiopharmaceuticals for research, diagnostic, and therapeutic uses. The Nuclear Services Group segment provides nuclear materials processing, environmental site restoration, and management and operating services; develops technology for nuclear power sources application; and designs, engineers, licenses, and manufactures nuclear reactors. The company was formerly known as The Babcock & Wilcox Company and changed its name to BWX Technologies, Inc. in June 2015. BWX Technologies, Inc. was founded in 1867 and is headquartered in Lynchburg, Virginia.
How the Company Makes MoneyBWXT generates revenue through a diversified business model that includes several key revenue streams. The Government segment contributes a significant portion of revenue, primarily through contracts with the U.S. Department of Defense for the design and production of nuclear reactors for naval vessels, as well as for other defense-related services. The Commercial segment earns revenue by providing engineering and manufacturing services to commercial nuclear power plants, including the supply of components and systems for reactor operations. Additionally, BWXT engages in advanced manufacturing processes, which can lead to increased efficiency and cost savings for its clients. The company benefits from long-term contracts and partnerships with government entities and commercial clients, which contribute to stable and predictable revenue. Furthermore, BWXT's focus on innovation and technology development in the nuclear sector positions it advantageously for future growth opportunities.

BWX Technologies Earnings Call Summary

Earnings Call Date:Feb 23, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Positive
The call presents a largely positive outlook: strong revenue, EBITDA, EPS and free cash flow growth in 2025, substantial backlog expansion (+50% total, +85% commercial), successful strategic acquisitions (AOT, Kinectrics), and robust commercial momentum (Q4 commercial revenue +95%). Management provided constructive 2026 guidance (high-teens revenue growth, low- to mid-teens EBITDA growth) and strengthened liquidity via a $1.25B convertible. Near-term challenges include government segment mix/margin pressure from new programs, early-stage lower-margin ramping for defense fuels and HPDU, Tech 99 regulatory/quality uncertainty (excluded from guidance), and modest operational constraints for AI in classified sites. On balance, the highlights materially outweigh the lowlights given strong financial performance, backlog and strategic wins, supporting a positive forward view.
Q4-2025 Updates
Positive Updates
Full-Year Financial Outperformance
FY2025 revenue grew 18%, adjusted EBITDA grew 15%, earnings per share grew 20%, and free cash flow grew 16%, all exceeding the company's initial guidance for the year.
Strong Backlog Growth
Total backlog ended 2025 at $7.3 billion, up 50% year-over-year, with commercial backlog of $1.7 billion up 85% YoY and up 16% sequentially, supporting multi-year revenue visibility.
Robust Quarterly Results
Q4 revenue was $886 million, up 19% year-over-year (organic revenue +4%). Adjusted EBITDA for the quarter was $148 million, up 13% YoY, and adjusted EPS was $1.08, up 17%.
Commercial Operations Momentum
Commercial operations revenue surged 95% in the quarter (31% organic growth). Segment adjusted EBITDA rose 87% YoY to $44 million with margin improvement to 14.9%. Book-to-bill in commercial nuclear power was over 2 in the quarter.
Medical Business Milestone
BWXT Medical achieved slightly more than $100 million of annual revenue, up about 20% YoY, driven by double-digit diagnostic isotope growth, increased actinium sales, and steady TheraSphere performance.
Strategic Acquisitions and Awards
Completed AOT and Kinectrics acquisitions enabling wins such as the $1.6 billion high-purity depleted uranium (HPDU) contract and the owner's engineer role for the Kozloduy AP1000 project; Kinectrics also contributed to international TSG and licensing capabilities.
Operational and Strategic Investments
Significant investments and openings in 2025: BWST Innovation Campus for advanced nuclear, Centrifuge manufacturing development facility completed in 7 months, new BWXT Digital Center, design of an HPDU manufacturing facility, and continued expansion at Cambridge plant.
Balance Sheet and Liquidity Strengthening
Completed a $1.25 billion 0% coupon convertible offering (with capped call increasing conversion price to >$396), used proceeds to refinance credit facilities, reduced cost of debt, and ended the year with $1.7 billion liquidity.
2026 Financial Guidance
Guidance for 2026: revenue ~ $3.75 billion (up high teens), adjusted EBITDA $645–$660 million (up low- to mid-teens), non-GAAP EPS $4.55–$4.70 (up mid- to high-teens), and free cash flow $305–$320 million (low- to mid-teens operating cash flow growth).
Delivery and Product Wins
Operational highlights include shipment of 2 large steam generators for CVN 81 and delivery of the first TRISO fuel core for Project Pele to Idaho National Lab; TRISO manufacturing for Antares is in progress targeting reactor criticality by July 4.
Negative Updates
Government Operations Near-Term Pressure
Government Operations revenue was down 1% in the quarter and adjusted EBITDA decreased 5%; segment margin (quarter) fell to 18.8% and management expects margins to be slightly lower in 2026 due to mix as new programs with lower initial profit recognition ramp.
Margin and Mix Headwinds from New Programs
New defense fuels and HPDU programs require infrastructure investment and start at lower initial margins; company expects some back-half weighting in 2026 results (~55% of EBITDA in H2) and Q1 2026 EBITDA/EPS to be flat to slightly up as mix normalizes.
Tech 99 Regulatory/Quality Uncertainty
Tech 99 medical product has not been submitted to the FDA and faces product quality issues (filtration, concentration) that management is addressing; Tech 99 revenues were not included in 2026 guidance, representing upside only if resolved.
Early-Stage Programs with Lower Front-End Margins
Defense fuels and HPDU contracts are at early negotiation/execution phases and currently contribute lower-margin activity as infrastructure and capacity ramp, creating short-term margin headwinds.
Regulatory/Competition Risk on Acquisition
Kinectrics acquisition is subject to review by the Canadian Competition Bureau (no updates reported), representing a potential regulatory overhang or delay risk.
Operational Constraints and Security Limits for Digital Initiatives
While AI/digital transformation is a stated priority, classified manufacturing environments impose constraints (e.g., limitations on WiFi/Bluetooth and security clearance considerations) that could slow certain deployments in government operations.
Company Guidance
BWXT guided to revenue of approximately $3.75 billion in 2026 (up high‑teens vs. 2025) with company adjusted EBITDA of $645–$660 million (up low‑ to mid‑teens) and non‑GAAP EPS of $4.55–$4.70 (up mid‑ to high‑teens); free cash flow is expected to be $305–$320 million (inclusive of low‑ to mid‑teens operating cash flow growth), CapEx roughly 6% of sales, and an adjusted tax rate of about 22%. Management expects Government Operations to grow low‑ to mid‑teens (with over half of that from defense fuels and HPDU) and Commercial Operations to grow ~25% (low‑double‑digit commercial power, high‑teens medical, full year contribution from Kinectrics), commercial segment margin improvement of ~100 bps in 2026, and a back‑half weighted year with ~55% of full‑year EBITDA in H2 (Q1 EBITDA and EPS expected roughly flat to slightly higher). Guidance is supported by a $7.3 billion backlog (up 50% YoY), $1.7 billion commercial backlog (up 85% YoY), year‑end liquidity of $1.7 billion and recent balance‑sheet actions including a $1.25 billion 0% convertible offering (post‑capped call conversion price > $396).

BWX Technologies Financial Statement Overview

Summary
Financials are solid but not pristine: steady 2022–2024 revenue growth and ~10% net margins support quality, while cash flow is positive in 2023–2025 but volatile (notably weaker FCF in 2025). The main offset is higher balance-sheet risk from re-levering in 2025 (debt-to-equity rising to ~1.64), reducing flexibility.
Income Statement
74
Positive
Revenue has grown steadily from 2022–2024 (mid-to-high single digit trajectory) and profitability remains solid, with net margins consistently around ~10%. However, profitability has softened versus 2020–2021 (lower net and EBITDA margins), and the 2025 annual gross profit and EBIT margin fields appear missing/zeroed in the data, reducing visibility into the latest period’s cost structure.
Balance Sheet
58
Neutral
Leverage is the main swing factor. Debt-to-equity improved meaningfully in 2024 (~1.0), but rose sharply again in 2025 (to ~1.64) alongside a large increase in total debt, signaling higher balance sheet risk. Equity has grown over time, but the recent re-levering reduces flexibility if rates stay higher or execution weakens.
Cash Flow
64
Positive
Cash generation is positive with healthy operating cash flow and free cash flow in 2023–2025, and free cash flow generally covers a meaningful portion of earnings (roughly ~0.58–0.62 in 2023–2025). The weakness is volatility: free cash flow fell sharply in 2025 (down ~36% YoY) and was very thin/negative in 2020–2022, showing sensitivity to working capital and/or investment cycles.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.20B2.70B2.50B2.23B2.12B
Gross Profit0.00655.21M620.59M551.93M550.28M
EBITDA404.46M474.06M447.00M424.63M500.55M
Net Income329.86M281.94M245.85M238.19M305.87M
Balance Sheet
Total Assets0.002.87B2.75B2.62B2.50B
Cash, Cash Equivalents and Short-Term Investments0.0074.11M78.62M39.05M37.70M
Total Debt2.02B1.06B1.21B1.29B1.19B
Total Liabilities3.04B1.79B1.81B1.87B1.86B
Stockholders Equity1.23B1.08B933.35M748.31M637.17M
Cash Flow
Free Cash Flow295.29M254.78M212.41M46.39M74.97M
Operating Cash Flow479.85M408.43M363.70M244.70M386.03M
Investing Cash Flow-742.11M-154.56M-155.64M-256.24M-304.65M
Financing Cash Flow693.64M-252.78M-169.37M13.95M-90.14M

BWX Technologies Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price206.44
Price Trends
50DMA
194.51
Positive
100DMA
192.72
Positive
200DMA
170.01
Positive
Market Momentum
MACD
1.21
Positive
RSI
48.06
Neutral
STOCH
64.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BWXT, the sentiment is Neutral. The current price of 206.44 is above the 20-day moving average (MA) of 202.89, above the 50-day MA of 194.51, and above the 200-day MA of 170.01, indicating a neutral trend. The MACD of 1.21 indicates Positive momentum. The RSI at 48.06 is Neutral, neither overbought nor oversold. The STOCH value of 64.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BWXT.

BWX Technologies Risk Analysis

BWX Technologies disclosed 29 risk factors in its most recent earnings report. BWX Technologies reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

BWX Technologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$102.87B24.9226.17%1.55%-0.14%72.35%
75
Outperform
$65.77B41.318.20%1.61%2.83%47.00%
74
Outperform
$94.50B22.6217.66%1.73%11.86%17.39%
74
Outperform
$149.51B30.2476.87%2.77%2.88%-35.15%
67
Neutral
$16.67B27.6012.42%1.53%2.60%-18.22%
64
Neutral
$18.49B60.4926.69%0.56%14.01%10.92%
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BWXT
BWX Technologies
198.38
95.11
92.10%
GD
General Dynamics
348.98
103.80
42.34%
LHX
L3Harris Technologies
355.14
154.17
76.71%
HII
Huntington Ingalls
438.01
266.55
155.45%
LMT
Lockheed Martin
660.62
225.00
51.65%
NOC
Northrop Grumman
725.39
273.70
60.59%

BWX Technologies Corporate Events

Business Operations and StrategyExecutive/Board Changes
BWX Technologies Adds Veteran Director to Board for Growth
Positive
Feb 20, 2026

On February 18, 2026, BWX Technologies’ board of directors voted to expand its membership from nine to ten and appointed aerospace and defense veteran Dan Jablonsky as a director, effective March 2, 2026, with his initial term running through the company’s 2026 annual shareholder meeting. The board determined that he is an independent director, named him to the audit and finance committee, and confirmed that he meets U.S. Securities and Exchange Commission requirements as an audit committee financial expert.

Jablonsky, formerly chief executive officer and chairman of Ursa Major and previously CEO of Maxar Technologies, brings deep experience in space propulsion, satellite imagery and complex corporate turnarounds, including leading Maxar through a $6.4 billion take-private transaction. His appointment is expected to strengthen BWXT’s board oversight and support the company’s strategy to accelerate growth in the space and defense sectors, aligning board expertise more closely with its expanding high-tech and national security-focused business portfolio.

The most recent analyst rating on (BWXT) stock is a Buy with a $231.00 price target. To see the full list of analyst forecasts on BWX Technologies stock, see the BWXT Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 24, 2026